• Molloy Research Lab

    Bowel cancer and Biomarker research

    About Us
  • Bioinformaticians needed

    Collaborate with us to improve patient care

  • Proteomic signatures

    Advanced technologies to understand cancer at an unprecedented depth


17,000 Australian's will be diagnosed with bowel cancer this year. Over 4,000 will die from their disease. We need to change this.

Our research is using molecular analyses to improve prevention, provide earlier diagnostic and better prognostic biomarkers and optimize treatments.

Pathophysiology of bowel polyps

Genomic and proteomic analysis is helping us understand why some polyps become malignant. This will allow improved prevention and better determine the risk of disease development.

Cancer metastasis

We need molecular markers to identify the risk of tumour dissemination in early stage disease. This will offer improved treatments leading to less recurrence and improvement is patient survival.

Microbiome and biomarkers

Gut microbes are associated with bowel cancers. How they contribute to carcinogenesis remains to be fully understood. We can measure their presence and are learning how to use them as biomarkers, and manipulate them through diet and interventions.


Some recent selected publications

The Molloy lab uses mass spectrometry for proteomic and metabolite analyses and genomics to study cancer and other diseases.

Our oncology publications are in the following cancers: colorectal, lung, thyroid, melanoma, mesothelioma, prostate, pancreatic.

We also use mass spectrometry to study other diseases including neurodegenerative diseases (MND, Alzheimer's) and diabetes.

The Molloy lab has also developed new technology approaches for proteomics including bioinformatic solutions

View all Publications

Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia

Molloy MP, Engel A

A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma.

Kao SC, Kirschner MB, Cooper WA, Tran T, Burgers S, Wright C, Korse T, van den Broek D, Edelman J, Vallely M, McCaughan B, Pavlakis N, Clarke S, Molloy MP, van Zandwijk N, Reid G.

Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis.

Krisp C, Parker R, Pascovici D, Hayward NK, Wilmott JS, Thompson JF, Mann GJ, Long GV, Scolyer RA, Molloy MP.

Multi-laboratory analysis of the variability of shipped samples for proteomics following non-cooled international transport.

Steffen P, Krisp C, Yi W, Yang P, Molloy MP, Schlüter H.

Quantitation of the anticancer drug abiraterone and its metabolite Δ(4)-abiraterone in human plasma using high-resolution mass spectrometry.

Bhatnagar A, McKay MJ, Crumbaker M, Ahire K, Karuso P, Gurney H, Molloy MP

Alternative assembly of respiratory complex II connects energy stress to metabolic checkpoints.

Bezawork-Geleta A, Wen H, Dong L, Yan B, Vider J, Boukalova S, Krobova L, Vanova K, Zobalova R, Sobol M, Hozak P, Novais SM, Caisova V, Abaffy P, Naraine R, Pang Y, Zaw T, Zhang P, Sindelka R, Kubista M, Zuryn S, Molloy MP, Berridge MV, Pacak K, Rohlena J, Park S, Neuzil J.

Contact Information

Call: +61299267870

Email: m.molloy@sydney.edu.au

Mark P Molloy


Mark is Head of the Bowel Cancer and Biomarker laboratory at the Kolling Institute, The University of Sydney, and the inaugural Lawrence Penn chair of Bowel Cancer Research. He is a translational biochemist and international expert in proteomic analysis with o


Official launch event for the Lawrence Penn chair of Bowel Cancer Research at The University of Sydney.

L to R: Julien Wiggens – CEO, Bowel Cancer Aust.
Professor Mark Molloy
June Penn
Lawrence Penn
Heather Penn
Richard Penn